NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Berek, J. S., Chen, L., Cristea, M., DeRosa, M., ElNaggar, A. C., Gershenson, D. M., Gray, H. J., Hakam, A., Jain, A., Leath, C. A., Liu, J., Mahdi, H., Matei, D., McHale, M., McLean, K., O'Malley, D. M., Penson, R. T., Percac-Lima, S., Ratner, E., Remmenga, S. W., Sabbatini, P., Werner, T. L., Zsiros, E., Burns, J. L., Engh, A. M. 2019; 17 (8): 896-+

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

View details for DOI 10.6004/jnccn.2019.0039

View details for Web of Science ID 000487240600004

View details for PubMedID 31390583